WRF
ITCI

Waddell & Reed Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Waddell & Reed Financial’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-94,500
Closed -$1.44M – 634
2016
Q3 		$1.44M Hold
94,500
– – ﹤0.01% 569
2016
Q2 		$3.67M Buy
94,500
+2,500
+3% +$89.8K 0.01% 526
2016
Q1 		$2.56M Hold
92,000
– – ﹤0.01% 565
2015
Q4 		$4.95M Sell
92,000
-34,800
-27% -$1.76M 0.01% 487
2015
Q3 		$5.08M Buy
+126,800
New +$4.14M 0.01% 494

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Waddell & Reed Financial's ITCI Position: Q4 2016 in Review

Waddell & Reed Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2016, closing a stake of 94,500 shares — an estimated $1.44M sold.

Waddell & Reed Financial first reported a position in ITCI in Q3 2015 and held it in 5 quarters. The position peaked at $5.08M in Q3 2015. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

  • Waddell & Reed Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2016 after selling out during the quarter.
  • Waddell & Reed Financial sold 94,500 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $1.44M.
  • Waddell & Reed Financial first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 5 quarters.
  • Waddell & Reed Financial's Intra-Cellular Therapies Inc. position peaked at $5.08M in Q3 2015.
  • 129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on Waddell & Reed Financial's 13F filing for Q4 2016, filed 14 Feb 2017.